Search

Your search keyword '"Bell, Robin J"' showing total 669 results
Start Over Author "Bell, Robin J"
669 results on '"Bell, Robin J"'

173. Ovarian status in healthy postmenopausal women

Author

Bell, Robin J., primary, Healy, David L., additional, Robertson, David M., additional, Jobling, Tom, additional, Oehler, Martin K., additional, Edwards, Andrew, additional, Shekleton, Paul, additional, Oldham, Jacqueline, additional, Piessens, Sofie, additional, Teoh, Mark, additional, Mamers, Pamela, additional, Taylor, Nancy, additional, and Walker, Frances, additional

Published
2009
Full Text
View/download PDF

180. Relaxin in paired samples of serum and milk from women after term and preterm delivery

Author

Eddie, Lawrence W., Sutton, Beverley, Fitzgerald, Stephen, Bell, Robin J., Johnston, Paul D., and Tregear, Geoffrey W.

Subjects
Relaxin -- Measurement, Breast milk -- Analysis, Health
Abstract

Relaxin is a substance that is found in breast milk and in the blood during and just after pregnancy. Relaxin is thought to help the dilation of the cervix during delivery. Although the source and role of relaxin in the breast is not understood, it is thought to be involved in the development of breast tissue. There is speculation that relaxin is synthesized in the breast milk for use by the breast tissue itself. Measurements of relaxin in the breast milk and blood were made in 12 women three days after a term delivery and in 16 women who delivered early (preterm). Relaxin concentrations remained similar in both delivery groups in breast milk and maternal blood. Relaxin was not found in the mother's blood six weeks after birth but was found in the breast milk of six out of eight term deliveries. A higher amount of relaxin, found in five out of six preterm deliveries, may be the consequence of a small patient sample. Relaxin was originally thought to be produced by the corpus luteum produced at conception. However, because relaxin is still present six weeks after the degeneration of the corpus luteum, it is hypothesized that relaxin must be produced elsewhere, namely in the breast.

Published
1989

188. Letter to the Editor

Author

Davis, Susan R., primary, Goldstat, Rebecca, additional, Papalia, Mary-Anne, additional, Shah, Sonal, additional, Kulkarni, Jayashri, additional, Donath, Susan, additional, and Bell, Robin J., additional

Published
2006
Full Text
View/download PDF

196. Testosterone Improves Antidepressant-Emergent Loss of Libido in Women: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Fooladi, Ensieh, Bell, Robin J., Jane, Fiona, Robinson, Penelope J., Kulkarni, Jayashri, and Davis, Susan R.

Subjects
*THERAPEUTIC use of testosterone, *LIBIDO, *WOMEN'S sexual behavior, *RANDOMIZED controlled trials, *SEXUAL dysfunction, *SEROTONIN uptake inhibitors
Abstract

Introduction Female sexual dysfunction is a side effect of selective serotonin reuptake inhibitor ( SSRI)/serotonin noradrenalin reuptake inhibitor ( SNRI) therapy. Aims The aim of this study is to investigate the efficacy of transdermal testosterone ( TT) as a treatment for SSRI/SNRI-emergent loss of libido. Methods This was a double-blind, randomized, placebo-controlled study. Forty-four women, aged 35-55 years, on a stable dose of SSRI or SNRI with treatment-emergent loss of libido were randomly allocated to treatment with a TT patch delivering 300 mcg of testosterone/day or an identical placebo patch ( Pl) for 12 weeks. Main Outcome Measures The primary outcome measure was the change in the Sabbatsberg Sexual Self-rating Scale ( SSS) total score over 12 weeks. The 4-week frequency of Satisfactory Sexual Events ( SSEs) and the Female Sexual Distress Scale- Revised ( FSDS-R) were also measured. Results At baseline, there were no differences between the treatment groups. At week 12, the change in the SSS score did not differ between the two groups. The increase in the 4-week frequency of SSEs was significantly greater for the TT group than for the Pl group (an increase of 2.3 events vs. 0.1, P = 0.02). The between-group difference in the change in the FSDS-R score approached statistical significance ( P = 0.06). The mean total serum testosterone level at 12 weeks in the TT group was 2.1 nmol/L. No women withdrew because of androgenic adverse events. Conclusions TT therapy resulted in a significant increase in the number of SSEs compared with Pl therapy in women with SSRI/SNRI-emergent loss of libido. The lack of improvement in the SSS total score may reflect lack of sensitivity of this instrument for the measurement of change in sexual function. This provides the first evidence that TT therapy may be a treatment option for women with SSRI/SNRI-emergent loss of libido who need to remain on their antidepressant therapy. Fooladi E, Bell RJ, Jane F, Robinson PJ, Kulkarni J, and Davis SR. Testosterone improves antidepressant-emergent loss of libido in women: Findings from a randomized, double-blind, placebo-controlled trial. J Sex Med 2014;11:831-839. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results